Ann: Security Class Reinstatement to Quotation- OPTOB, page-656

I agree—I posted similar sentiments here: https://hotcopper.com.au/posts/77502140/single. Basically, the masked data to means that the 52-week combined treatment merged with control monotherapy arms performs better than the mono only P2 VEGF-A only 24-week arm. Given that P3 is essentially split into two treatment arms and one control (a 1:1:1 ratio), and as the study is masked, we are seeing improved results, the treatment arms is, as you say, clearly working.

It is hard to see these safety statements as anything other than "it works, we are not stopping, there is improvement"; the only other explanation I can imagine would be that the control arm (which comprises only 33% of the total) is significantly overperforming and thus treatment arms underperforming, if that was true then wouldn't the safety team stop the trial?

While there are no absolutes, I just see that the only question that really remains is the magnitude of the effect. We could still be disappointed—for example, only a non-clinical 2-letter improvement—but as you say, everything is pointing very much towards 4+; I believe a full line (5+) is more likely.




f